Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mXELOXIRI Reintroduction in mCRC
NCT04508452Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, irinotecan and bevacizumab in metastatic colorectal cancer (mCRC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Reintroduction Rate up to 18 months. Status: unknown.
02
Drugs
capecitabineoxaliplatinirinotecanbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04508452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508452.